# Telegraph Hill Partners

> Telegraph Hill Partners is a VC fund backing Biotechnology and Health Care. See 52 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 52
- Last investment: Jun 2026
- Lead investor: 71%
- Fund size: $525M
- Last fund: Jul 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/telegraph-hill-partners/
- Website: http://www.thpartners.net
- Facebook: https://www.facebook.com/pages/Telegraph-Hill-Partners/133846693334685

Telegraph Hill Partners is a venture capital firm that invests behind technology leaders in the life science, medical devices, and healthcare industries. THP was founded in 2001 by J. Matthew Mackowski, Robert Shepler, Dr. Thomas Raffin, and Deval Lashkari, and is headquartered in San Francisco, California.

## Contacts

5 contacts available for Telegraph Hill Partners. Shizune tracks 9 team members at Telegraph Hill Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/telegraph-hill?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 19 | 37% |
| Health Care | 18 | 35% |
| Medical | 9 | 17% |
| Medical Device | 8 | 15% |
| Life Science | 6 | 12% |

38 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 13 | 25% |
| Series A | 8 | 15% |
| Series B | 7 | 13% |
| Venture - Series Unknown | 5 | 10% |
| Series C | 3 | 6% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 28 | 54% |
| Canada | 1 | 2% |
| United Kingdom | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alexander C. Herzick | Partner | 6 | https://shizune.co/investors/profile/alexander-c-herzick |
| Deval A. Lashkari | Senior Partner | 5 | https://shizune.co/investors/profile/deval-a-lashkari |
| Jeanette M. Welsh | Partner | 1 | https://shizune.co/investors/profile/jeanette-m-welsh |
| Rob C. Hart | Partner | 4 | https://shizune.co/investors/profile/rob-c-hart |
| Thomas A. Raffin | Senior Partner/Co-Founder, | 9 | https://shizune.co/investors/profile/thomas-a-raffin |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| etherFAX | etherFAX they digitize workflows and optimize business processes. They provide hybrid-cloud fax solutions supporting healthcare enterprises, documents  directly to  applications and devices . |  | Venture - Series Unknown | Jun 16, 2026 |  |
| Kytopen | Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing. The company provides non-viral gene delivery systems that facilitate the delivery of mRNA, DNA, and CRISPR Cas9 RNP into cells while retaining cell functionality. Its Flowfect® technology allows high-throughput transfections and scalable optimizationfrom small experiments to large-scale manufacturing.Kytopen’s platforms include Flowfect Discover™ for automated small-volume screening and Flowfect TX® for large-scale delivery, supporting drug discovery and process development. The systems integrate electrical, mechanical, and chemical forces to fine-tune gene delivery, enabling controlled and predictable scaling. The company’s solutions focus on removing bottlenecks in gene delivery and streamlining the transition from laboratory research to therapeutic production. |  | Series B | Apr 07, 2026 |  |
| Promptly | Promptly is a web-based patient experience and automation suite designed for medical practices. |  | Series A | Jun 27, 2024 |  |
| Argonaut Manufacturing Services | Argonaut provides contract manufacturing for biopharmaceutical, diagnostics and life science organizations. The company's services include high-yield aseptic fill/finish, reagent formulation, filling, kitting, lyophilization, and analytical support. It provides a wide range of diagnostics and drug products for diverse outsourcing needs. | $45M | Series A | Mar 05, 2024 |  |
| Cell Microsystems | Cell Microsystems is an early growth stage company that develops, manufactures, and markets innovative products for single-cell biology. The company’s proprietary CellRaft™ Technology enables high-efficiency sorting and isolation of single cells under standard culture conditions resulting in unperturbed phenotypes and high viability. Coupled withthe company’s automated imaging platform, a user can select a cell in real-time and ‘track and trace’ that cell through imaging, collection, and downstream analysis. By sorting during real-time imaging, no cells are wasted enabling single-cell isolation from even small, precious samples. The CellRaft Technology offers scalable solutions making cell separation technology available for every lab. | $6.5M | Series B | Aug 23, 2023 |  |
| Panome Bio | Panome Bio is a biomarker discovery platform offering biomarker analysis. The company's services also include metabolomics, lipidomics, and proteomics screening solutions through untargeted analysis and proprietary computational methods. Panome Bio was founded in 2022 and is headquartered in Saint Louis, Missouri. | $6M | Series A | Feb 24, 2023 |  |
| Panome Bio | Panome Bio is a biomarker discovery platform offering biomarker analysis. The company's services also include metabolomics, lipidomics, and proteomics screening solutions through untargeted analysis and proprietary computational methods. Panome Bio was founded in 2022 and is headquartered in Saint Louis, Missouri. | $6M | Series A | Feb 24, 2023 |  |
| Panome Bio | Panome Bio is a biomarker discovery platform offering biomarker analysis. The company's services also include metabolomics, lipidomics, and proteomics screening solutions through untargeted analysis and proprietary computational methods. Panome Bio was founded in 2022 and is headquartered in Saint Louis, Missouri. | $6M | Series A | Feb 24, 2023 |  |
| Argonaut Manufacturing Services | Argonaut provides contract manufacturing for biopharmaceutical, diagnostics and life science organizations. The company's services include high-yield aseptic fill/finish, reagent formulation, filling, kitting, lyophilization, and analytical support. It provides a wide range of diagnostics and drug products for diverse outsourcing needs. |  |  | Jan 10, 2023 |  |
| Emerging Therapy Solutions | Emerging Therapy Solutions is an insurance company that specializes in the full management of gene and cell therapy for payers. It focuses on the development of proprietary targeting and segmentation algorithms to break down rare conditions. The company was founded in 2018 and headquartered in Minneapolis, Minnesota. | $3M | Venture - Series Unknown | Dec 20, 2022 |  |

10 of 52 investments shown.

## Co-investors
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 3 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 3 deals together
- [Psilos Group](https://shizune.co/investors/profile/psilos-group) — VC Fund, 3 deals together
- [Saints Capital](https://shizune.co/investors/profile/saints-capital) — VC Fund, 3 deals together
- [Adams Street Partners](https://shizune.co/investors/profile/adams-street-partners) — VC Fund, 2 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Telegraph Hill Partners invest in?

Telegraph Hill Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 52 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Telegraph Hill Partners?

Public channels for Telegraph Hill Partners include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Telegraph Hill Partners?

The team at Telegraph Hill Partners includes Alexander C. Herzick (Partner), Deval A. Lashkari (Senior Partner) and Jeanette M. Welsh (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co